Begelomab

DB13241InvestigationalProtein Based Therapies

Begelomab is a murine monoclonal antibody against CD26.

Mechanism
Curator reviewed
Also known as
IMMUNOGLOBULIN G2B-KAPPA, ANTI-(HOMO SAPIENS DPP4(DIPEPTIDYLPEPTIDASE 4, DIPEPTIDYLPEPTIDASE IV, ADENOSINE DEAMINASE COMPLEXING PROTEIN 2, ADCP2, TP103, T CELL ACTIVATION ANTIGEN CD26, CD26)), MUS MUSCULUS MONOCLONAL ANTIBODY

Resolves to

Compound
UNII360N6PY2A1CAS1403744-56-8
Clinical / RWD
ATCL04AG07
Targets
P27487DPP4

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
363Drug interactionsStructured to mechanism, not free text
Sign in
1Clinical trialPhase, status and sponsor resolved per trial
Sign in
1ATC codeIncluding every combination product, plus 9 drug categories
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Begelomab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In